Zolpidem tartrate 12.5 MG Extended Release Tablet
1 INDICATIONS AND USAGE Zolpidem tartrate extended-release tablets are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. Zolpidem tartrate extended-release tablets, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )
Actavis Pharma, Inc.
ROUND YELLOW A1
A1 ROUND YELLOW
Related Pills
Zolpidem tartrate 12.5 MG Extended Release Tablet
Actavis Elizabeth LLC
vitamin d folic acid
amella pharma llc
anastrozole 1 MG Oral Tablet
Sun Pharmaceutical Industries Limited
low dose aspirin aspirin tablet coated
akron phama
alyacen 777 norethindrone and ethinyl estradiol kit alyacen 135 norethindrone and ethinyl estradiol kit
glenmark pharmaceuticals inc., usa
amlodipine as amlodipine besylate 10 MG Oral Tablet
Mylan Pharmaceuticals Inc.
Zolpidem Tartrate Zolpidem tartrate 6.25 MG Extended Release Oral Tablet
Par Pharmaceutical, Inc.
amlodipine besylate tablet
mylan pharmaceuticals inc.
alprazolam tablet
mylan pharmaceuticals inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Zolpidem Tartrate Extended-Release Tablets USP, 6.25 mg are composed of two portions* and are white, round, biconvex, unscored, coated tablets debossed with A2 on one side and plain on the other side and supplied as: NDC Number Size 0228-3481-11 bottle of 100 Each tablet contains 6.25 mg of zolpidem tartrate, USP. Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg are composed of two portions* and are yellow, round, biconvex, unscored, coated tablets debossed with A1 on one side and plain on the other side and supplied as: NDC Number Size 0228-3482-11 bottle of 100 Each tablet contains 12.5 mg of zolpidem tartrate, USP. *Portions are covered by the coating and are indistinguishable. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant, child-resistant container as defined in the USP.
More pills like ROUND A1